Share on StockTwits

Research analysts at Cowen and Company initiated coverage on shares of Insmed (NASDAQ:INSM) in a report released on Friday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock.

Insmed (NASDAQ:INSM) opened at 13.96 on Friday. Insmed has a 1-year low of $11.25 and a 1-year high of $22.29. The stock’s 50-day moving average is $14.6 and its 200-day moving average is $15.92. The company’s market cap is $548.4 million.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by $0.13. Analysts expect that Insmed will post $-1.86 EPS for the current fiscal year.

Insmed Incorporated is a biopharmaceutical company focused on patients suffering with lung diseases through the development and commercialization of targeted inhalation therapies.

The Fly On The Wall

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with Analyst Ratings Network's FREE daily email newsletter.